Digital Pharma’s next security problem isn’t the code. It’s what the... As AI becomes embedded throughout development, innovation must be matched by equally sophisticated approaches to software security.
Market Access Navigating Europe's AI regulatory labyrinth: A strategic gui... For US drug developers, bringing AI tools across the Atlantic introduces steep regulatory hurdles.
Digital What US healthcare companies and medical researchers need to... How Italy’s pioneering AI Law and the EU AI Act impacts US healthcare companies and medical researchers operating in Italy.
Market Access Balancing innovation and safety: The impact of Medtech regul... The Medtech sector is currently at a crossroads, facing a potential choice between rapid technological advancement and strict regulatory oversight.
Digital Considering current legal risks from the use of AI in the li... The use of artificial intelligence (AI) in the life sciences sector is increasing, and its applications may be transformative.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.